NASDAQ · KODHealthcareBiotechnology

Kodiak Sciences financials

$91.12+1.33%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$0.00$0.00$0.00$0.00$0.00———
Gross profit$0.00$0.00$0.00$0.00$0.00———
Gross margin————————
Operating income-$234.4M-$186.8M-$277.3M-$341.4M-$267.1M-$136.0M-$49.2M-$26.4M
Net income-$230.0M-$176.2M-$260.5M-$333.8M-$267.0M-$133.1M-$47.4M-$41.4M
Net margin————————
Diluted EPS$-4.32$-3.35$-4.97$-6.39$-5.16$-2.91$-1.25$-2.77
EBITDA-$216.1M-$168.1M-$259.0M-$337.6M-$266.0M-$135.5M-$48.7M-$25.9M
Operating cash flow-$136.0M-$117.3M-$154.2M-$206.5M-$182.3M-$83.4M-$39.1M-$29.0M
Free cash flow-$136.5M-$117.7M-$195.6M-$253.8M-$245.6M-$90.4M-$39.6M-$29.6M
Diluted shares53.2M52.6M52.4M52.2M51.8M45.7M37.9M15.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$209.9M$168.1M$285.5M$190.4M$731.5M$944.4M
Short-term investments$0.00$0.00$0.00$288.5M$0.00$24.6M
Total debt$0.00$0.00$0.00$0.00$0.00$0.00
Total assets$351.5M$335.6M$479.4M$666.6M$904.2M$1.07B
Total liabilities$194.2M$185.3M$213.6M$230.5M$240.9M$206.6M
Shareholders' equity$157.4M$150.3M$265.8M$436.2M$663.3M$860.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology